

## INDEPENDENT AUDITOR'S REPORT

To the Members of  
**AIMIL PHARMACEUTICALS (INDIA) LIMITED**  
Report on the Audit of the Financial Statements

### Opinion

We have audited the accompanying financial statements of **AIMIL PHARMACEUTICALS (INDIA) LIMITED ("the Company")**, which comprise the Balance Sheet as at 31<sup>st</sup> March, 2022, the statement of Profit and Loss, and the statement of Cash Flows for the year then ended and notes to the financial statements, including a summary of significant accounting policies and other explanatory information.

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid financial statements give the information required by the Companies Act, 2013 ("the Act") in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India, of the state of affairs of the Company as at March 31, 2022, and its financial performance and its cash flows for the year ended on that date.

### Basis of Opinion

We conducted our audit in accordance with the Standards on Auditing specified under section 143(10) of Companies Act, 2013 (SAs). Our responsibilities under those Standards are further described in the *Auditor's Responsibilities for the Audit of the Financial Statements* section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India (ICAI) together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act and the Rules made thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the ICAI's Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the financial statements.

### Information Other than the Financial Statements and Auditor's Report Thereon

The Company's Management and Board of Directors are responsible for the other information. The other information comprises the information included in the Company's annual report, but does not include the financial statements and our auditor's report thereon.

Our opinion on the standalone financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.



In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained during the course of our audit or otherwise appears to be materially misstated. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

### **Management's Responsibility for the Financial Statements**

The Company's Management and Board of Directors are responsible for the matters stated in Section 134(5) of the Companies Act, 2013 ("the Act") with respect to the preparation of these financial statements that give a true and fair view of the financial position, financial performance and cash flows of the Company in accordance with the accounting principles generally accepted in India, including the accounting standards specified under section 133 of the Act. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, Management and Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors is responsible for overseeing the Company's financial reporting process.

### **Auditor's Responsibilities for the Audit of the Financial Statements**

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial Statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide basis for our opinion. The





risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentation, or the override of internal control.

- Obtain an understanding of internal financial controls relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls system in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by Management and Board of Directors.
- Conclude on the appropriateness of Management and Board of Directors use of the going concern basis of accounting in preparation of financial statements and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the financial statements of the current period and are therefore the key audit matters. We describe these matters in our auditor's report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communications.



## Report on Other Legal and Regulatory Requirements

1. As required by the Companies (Auditor's Report) Order, 2020 ("the Order") issued by the Central Government of India in terms of section 143(11) of the Act, and on the basis of such checks of the books and records of the company as we considered appropriate and according to the information and explanations given to us, we give in the "**Annexure A**", a statement on the matters specified in the paragraph 3 and 4 of the order.
2. As required by Section 143(3) of the Act, we report that:
  - a. We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit.
  - b. In our opinion proper books of account as required by law have been kept by the Company so far as it appears from our examination of those books;
  - c. The balance sheet, statement of profit and loss and the cash flow statement dealt with by this report are in agreement with the books of account;
  - d. In our opinion, the aforesaid financial statements comply with the Accounting Standards specified under Section 133 of the Act read with Rule 7 of the Companies (Accounts) Rules, 2014 issued thereunder;
  - e. On the basis of the written representation received from the directors as on 31<sup>st</sup> March 2022 taken on record by the Board of Directors, none of the directors is disqualified as on 31<sup>st</sup> March 2022 from being appointed as a director in terms of Section 164 (2) of the Act;
  - f. With respect to the adequacy of the internal financial controls over financial reporting of the Company and the operating effectiveness of such controls, refer to our separate report in "**Annexure B**"; Our report expresses an unmodified opinion on the adequacy and operating effectiveness of the Company's internal financial controls over financial reporting.
  - g. With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, as amended, in our opinion and to the best of our information and according to the explanation given to us:
    - i. The Company has disclosed details regarding the impact of pending litigations on its financial position.
    - ii. The Company did not have any long-term contracts including derivative contracts for which there were any material foreseeable losses.
    - iii. There were no amounts which were required to be transferred to Investor Education and Protection Fund by the Company.
    - iv. (a) The management has represented that, to the best of its knowledge and belief, no funds have been advanced or loaned or invested (either from borrowed funds or share premium or any other sources or kind of funds) by the company to or in any other person(s) or





entity(ies), including foreign entities ("Intermediaries"), with the understanding, whether recorded in writing or otherwise, that the Intermediary shall, whether, directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the company ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries;

(b) The management has represented, that, to the best of its knowledge and belief, no funds have been received by the company from any person(s) or entity(ies), including foreign entities ("Funding Parties"), with the understanding, whether recorded in writing or otherwise, that the company shall, whether, directly or indirectly, lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries; and

(c) Based on such audit procedures that the auditor has considered reasonable and appropriate in the circumstances, nothing has come to their notice that has caused them to believe that the representations under sub-clause (a) and (b) contain any material mis-statement.

v. The company has not declared or paid any dividend during the year in contravention of the provisions of section 123 of the Companies Act, 2013.

**For AMBANI & ASSOCIATES LLP**

Chartered Accountants

(Firm Registration No.: 016923N)

 **HITESH AMBANI**  
Designated Partner

Membership No.: 506267

UDIN: 22506267BDPJVH4906

Place: New Delhi

Date: 21/09/2022

## **Annexure A to the Independent Auditor's Report**

(Referred to in paragraph 1 under 'Report on Other Legal and Regulatory Requirements' section of our report of even date)

Report on Companies (Auditor's Report) Order, 2020 ('the Order') issued by the Central Government in terms of Section 143(11) of the Companies Act, 2013 ('the Act') of **AIMIL PHARMACEUTICALS (INDIA) LIMITED ('the Company')**

- 1 a) (i) The Company has maintained proper records showing full particulars, including quantitative details and situation of Property, Plant and Equipment;  
  
(ii) The Company has maintained proper records showing full particulars of intangible assets;
- b) Property, Plant and Equipment were physically verified during the year by the Management in accordance with a regular programme of verification which, in our opinion, provides for physical verification of all the Property, Plant and Equipment at reasonable intervals. According to the information and explanations given to us, no material discrepancies were noticed on such verification.
- c) According to the information and explanations given to us, the records examined by us and based on the examination of the conveyance deeds provided to us, we report that title deeds, comprising all the immovable properties of land & buildings which are free hold, are held in the name of the company as at the balance sheet date.
- d) According to the information and explanations given to us, the records examined by us, the Company has not revalued its Property, Plant and Equipment (including Right of Use assets) or intangible assets.
- e) According to the information and explanations given to us, no proceedings have been initiated or are pending against the company for holding any Benami property under the Prohibition of Benami Property Transactions Act, 1988 and rules made thereunder.
- 2 a) As explained to us, the inventories (excluding goods in transit) were physically verified during the year by the Management at reasonable intervals and in our opinion, the coverage and procedure of such verification by the management is appropriate and no discrepancies of 10% or more in the aggregate for each class of inventory were noticed.
- b) As per the information and explanation given to us, the company has been sanctioned working capital limits in excess of five crore rupees, in aggregate, from bank but no security of current assets was required to be provided by the company and correspondingly no quarterly returns or statements were required to be filed by the company.
3. As per the information and explanation given to us, the company has not made investments in, provided any guarantee or security or granted any loans or advances in the nature of loans, secured or unsecured, to companies, firms, Limited Liability Partnerships or any other parties.





Therefore, the provisions of clauses 3(iii), (iii)(a)(A), (iii)(a)(B), (iii)(b), (iii)(c), (iii)(d), (iii)(e) and (iii)(f) of the said order are not applicable to the company.

4. In our opinion and according to the information and explanations given to us, the Company has complied with the provisions of Sections 185 and 186 of the Act in respect of grant of loans, making investments and providing guarantees and securities, as applicable.
5. The Company has not accepted deposits from the public with in meaning of sections 73, 74, 75 and 76 of the Act and rules framed there under to the extent notified during the year and does not have any unclaimed deposits as at March 31, 2022 and therefore, the provisions of the clause 3 (v) of the Order are not applicable to the Company.
6. The Central Government has prescribed the maintenance of cost records under sub-section (1) of Section 148 of the Act, for services rendered by the company.
7. According to the information and explanations given to us, in respect of statutory dues:
  - a) The Company has generally been regular in depositing undisputed statutory dues, including Goods and Services Tax, Provident Fund, Employees' State Insurance, Income Tax, duty of Customs, Cess and other material statutory dues applicable to it with the appropriate authorities.
  - b) According to the information and explanations given to us, there are no material dues of Goods and Services Tax, Provident Fund, Employees' State Insurance, Income Tax, Sales Tax, Service tax, duty of customs, value added tax, cess which have not been deposited with the appropriate authority on account of any disputes.
8. In our opinion and according to the information and explanations given to us, the Company has recorded all the transactions properly in the books of account and does not have any unrecorded transactions and therefore, the Company has not surrendered or disclosed any unrecorded transaction as income during the year in the tax assessments under the Income Tax Act, 1961 (43 of 1961).
9. In our opinion and according to the information and explanations given to us,
  - a) The Company has not defaulted in repayment of loans or other borrowings or in the payment of interest thereon to any lender.
  - b) The Company is not a declared willful defaulter by any bank or financial institution or other lender.
  - c) The term loans taken by the Company were applied for the purpose for which the loans were obtained;
  - d) Funds raised on short term basis by the Company have not been utilized for long term purposes;
  - e) The company does not have any subsidiary, joint venture or associate company. The company



has not raised any money from any person or entity for the account of or to pay the obligations of its associates.

- f) The company does not have any subsidiary or joint venture, it has two, associate companies namely M/s Aimil Ayouthveda India Ltd and M/s Aimil Marketing Services Pvt Ltd. The company has not raised any loans during the year by pledging securities held in their associate companies.
- 10.(a) The Company has not raised moneys by way of initial public offer or further public offer (including debt instruments) and hence reporting under clause 3 (x)(a) of the Order is not applicable.
- b) During the year, the Company has not made any preferential allotment or private placement of shares or convertible debentures (fully, partially or optionally convertible) and hence reporting under clause 3(x)(b) of the Order is not applicable to the Company.
11. (a) Based on examination of the books and records of the Company, and according to the information and explanations given to us, no fraud by the Company or on the Company has been noticed or reported during the course of the audit.
- (b) No report under Sub Section (12) of Section 143 of the Companies Act, has been filed in Form ADT-4 as prescribed under rule 13 of Companies Act (Audit and Auditors) Rules, 2014 with Central Government.
- (c) We have taken into consideration the whistle blower complaints received by the Company during the year while determining the nature, timing and extent of our audit procedures.
12. The Company is not a Nidhi Company and hence reporting under clause 3(xii) of the Order is not applicable.
13. In our opinion and according to the information and explanations given to us the Company is in compliance with Section 177 and 188 of the Act, where applicable, for all transactions with the related parties and the details of related party transactions have been disclosed in the financial statements as required by the applicable accounting standards.
14. (a) The Central Government has not prescribed to appoint internal auditor under section 138 of the Act, for any of the services rendered by the company.
- b) This clause is not applicable to the company.
15. In our opinion and according to the information and explanations given to us, during the year the Company has not entered into any non-cash transactions with its Directors or persons connected to its Directors and hence provisions of Section 192 of the Act are not applicable.
16. (a) The Company is not registered under Section 45-I of the Reserve Bank of India Act, 1934 and hence reporting under clauses 3(xvi)(b), (xvi)(c) and (xvi)(d) of the Order are not applicable.
17. The Company has not incurred any cash losses in the financial year.





18. No statement of resignation has been filed by the Statutory Auditor during the year and hence reporting under clause 3(xviii) is not applicable.
19. On the basis of the financial ratios, ageing and expected dates of realization of financial assets and payment of financial liabilities, other information accompanying the financial statements, our knowledge of the Board of Directors and management plans, we are of the opinion that no material uncertainty exists as on the date of the audit report and that the Company is capable of meeting its liabilities existing at the date of balance sheet as and when they fall due within a period of one year from the balance sheet date.
20. (a) The Company's Net worth does not exceed Rs 500 crores, Turnover does not exceed Rs 1000 crores and Net profit does not exceed Rs 5 crores during immediately preceding financial year, therefore provisions of section 135 of Companies Act, 2013 is not applicable to the company for the financials year 2021-2022.
- b) This clause is not applicable to the Company.

Place: New Delhi  
Date: 21/09/2022

For **AMBANI & ASSOCIATES LLP**

Chartered Accountants

(Firm Registration No.: 016923N)



**HITESH AMBANI**

Designated Partner

Membership No.: 506267

UDIN: 22506267BDPJVH4906

## **Annexure B to the Independent Auditor's Report**

### **Report on the Internal Financial Controls under Clause (i) of Sub-section 3 of Section 143 of the Companies Act, 2013 ("the Act")**

We have audited the internal financial controls over financial reporting of **AIMIL PHARMACEUTICALS (INDIA) LIMITED ("the Company")** as of 31 March 2022 in conjunction with our audit of the financial statements of the Company for the year ended on that date.

#### **Management's Responsibility for Internal Financial Controls**

The Board of Directors of the company is responsible for establishing and maintaining internal financial controls based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls over Financial Reporting issued by the Institute of Chartered Accountants of India ('ICAI'). These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to company's policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Companies Act, 2013.

#### **Auditor's Responsibility**

Our responsibility is to express an opinion on the Company's internal financial controls over financial reporting based on our audit. We conducted our audit in accordance with the Guidance Note on Audit of Internal Financial Controls over Financial Reporting (the "Guidance Note") and the Standards on Auditing, issued by ICAI and deemed to be prescribed under section 143(10) of the Companies Act, 2013, to the extent applicable to an audit of internal financial controls. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls over financial reporting was established and maintained and if such controls operated effectively in all material respects.

Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial controls system over financial reporting and their operating effectiveness. Our audit of internal financial controls over financial reporting included obtaining an understanding of internal financial controls over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the Company's internal financial controls system over financial reporting.

#### **Meaning of Internal Financial Controls Over Financial Reporting**





A company's internal financial control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal financial control over financial reporting includes those policies and procedures that (i) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of standalone financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.

### **Inherent Limitations of Internal Financial Controls Over Financial Reporting**

Because of the inherent limitations of internal financial controls over financial reporting, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls over financial reporting to future periods are subject to the risk that the internal financial control over financial reporting may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

### **Opinion**

In our opinion, to the best of our information and according to the explanations given to us, the Company has, in all material respects, an adequate internal financial controls system over financial reporting and such internal financial controls over financial reporting were operating effectively as at March 31, 2022, based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India.

For **AMBANI & ASSOCIATES LLP**  
Chartered Accountants  
(Firm Registration No.: 016923N)



**HITESH AMBANI**  
Designated Partner

Membership No.: 506267  
UDIN: 22506267BDPJVH4906

Place: New Delhi  
Date: 21/09/2022






**AIMIL PHARMACEUTICALS (INDIA) LIMITED**

2994/4, STREET NO-17, RANJEET NAGAR, NEW DELHI - 110008

CIN - U24231DL1984PLC019461

BALANCE SHEET AS AT 31st March, 2022

(' in lakhs, unless otherwise stated)

	PARTICULARS	Note No.	AS AT 31.03.2022	AS AT 31.03.2021
I	<b>EQUITY AND LIABILITIES</b>			
1	<b>SHAREHOLDER'S FUNDS</b>			
	(a) Share Capital	3	1,220.56	1,250.56
	(b) Reserves and Surplus	4	2,415.15	2,060.12
	(c) Money received against share warrants		-	-
2	<b>SHARE APPLICATION MONEY PENDING ALLOTMENT</b>		-	-
3	<b>NON CURRENT LIABILITIES</b>			
	(a) Long-Term Borrowings	5	348.47	464.02
	(b) Deferred Tax Liabilities (Net)	6	93.05	47.93
	(c) Other Long Term Liabilities	7	5,413.43	4,120.20
	(d) Long Term Provisions		-	-
4	<b>CURRENT LIABILITIES</b>			
	(a) Short-Term Borrowings	8	5,561.00	4,535.61
	(b) Trade Payables	9		
	- (A) total outstanding dues of micro enterprises and small enterprises and		57.63	54.55
	- (B) total outstanding dues of creditors other than micro enterprises and small enterprises		3,507.18	3,260.09
	(c) Other Current Liabilities	10	1,030.51	1,021.85
	(d) Short Term Provisions	11	1,356.98	1,199.29
	<b>TOTAL</b> Rs...		<b>21,003.95</b>	<b>18,014.22</b>
II	<b>ASSETS</b>			
1	<b>PROPERTY, PLANT &amp; EQUIPMENTS AND INTANGIBLE ASSETS</b>			
	(a) Property, Plant & Equipments :			
	(i) Tangible Assets	12	2,592.59	2,514.17
	(ii) Intangible Assets		2.20	1.68
	(iii) Capital work in Progress	12	308.89	-
	(iv) Intangible Assets under development		-	-
	(b) Non Current Investments		-	-
	(c) Deferred Tax Assets (Net)		-	-
	(d) Long-Term Loans and Advances		-	-
	(e) Other Non-Current Assets	13	1,506.43	1,656.65
2	<b>CURRENT ASSETS</b>			
	(a) Current Investments		-	-
	(b) Inventories	14	4,518.94	3,162.59
	(c) Trade Receivables	15	11,657.28	10,296.92
	(d) Cash and Cash Equivalents	16	74.43	39.42
	(e) Short-Term Loans and Advances	17	343.19	342.78
	(f) Other Current Assets		-	-
	<b>TOTAL</b> Rs...		<b>21,003.95</b>	<b>18,014.22</b>
	<b>SIGNIFICANT ACCOUNTING POLICIES</b>	1		
	<b>NOTES TO ACCOUNTS</b>	2-24		
	<b>ACCOMPANYING NOTES ARE INTEGRAL PART OF FINANCIAL STATEMENTS</b>			
	As Per Our Report of Even Date Attached			
	Ambani & Associates LLP			For and on behalf of the Board
	Chartered Accountants			
	FRN - 016923N			
	 Hitesh Ambani Designated Partner (MN-506267)		 Kanwal Kumar Sharma (Managing Director) DIN - 00526387 B-34, Surya Enclave, New Multan Nagar, Delhi-56	 Pankaj Marwaha (Director - Marketing) DIN - 00526342 1313, Sector-19 B, Chandigarh-160019
	Place: New Delhi Date: 21st Sep. 2022 UDIN: 22506267BDPJVH4906			





AIMIL PHARMACEUTICALS (INDIA) LIMITED

2994/4, STREET NO-17, RANJEET NAGAR, NEW DELHI - 110008

CIN - U24231DL1984PLC019461

PROFIT AND LOSS ACCOUNT FOR THE PERIOD 1st APRIL 2021 TO 31st MARCH 2022

( in lakhs, unless otherwise stated)

PARTICULARS		Note No.	YEAR ENDED 31.03.2022	YEAR ENDED 31.03.2021
I	Revenue from operations	18	44,705.68	40,231.81
II	Other income	19	53.54	48.18
III.	<b>Total Income</b>		<b>44,759.22</b>	<b>40,279.99</b>
IV.	<b>EXPENDITURE</b>			
	Cost of Materials Consumed	20	9,309.48	7,636.18
	Purchases of Stock -in-Trade		1,424.10	1,657.48
	Changes in Inventories of Finished Goods and Stock-in-Process	21	(635.68)	(228.39)
	Employee Benefits Expense	22	11,581.55	9,758.86
	Finance Costs	23	1,175.22	1,103.54
	Depreciation		354.15	363.68
	Other Expenses	24	20,916.67	19,628.29
	<b>Total Expenses</b>		<b>44,125.49</b>	<b>39,919.65</b>
V.	<b>Profit Before exceptional and extraordinary items and tax ( III - IV )</b>		<b>633.73</b>	<b>360.34</b>
VI.	Exceptional Items		-	-
VII.	<b>Profit Before extraordinary items and tax ( V - VI )</b>		<b>633.73</b>	<b>360.34</b>
VIII.	Extraordinary Items		-	-
IX	<b>Profit before Tax ( VII-VIII)</b>		<b>633.73</b>	<b>360.34</b>
X	<b>Tax Expenses</b>			
	(1) Current Tax		233.59	94.89
	(2) Deferred tax		45.12	23.68
	<b>Total Tax Expenses</b>		<b>278.71</b>	<b>118.56</b>
XI	<b>Profit (Loss) for the period from continuing operations (IX-X)</b>		<b>355.02</b>	<b>241.77</b>
XII	Profit/(loss) from discontinuing operations		-	-
XIII	Tax expense of discontinuing operations		-	-
XIV	<b>Profit/(loss) from Discontinuing operations (after tax) (XII-XIII)</b>		<b>-</b>	<b>-</b>
XV	<b>Profit (Loss) for the period (XI + XIV)</b>		<b>355.02</b>	<b>241.77</b>
XVI	Earnings per equity share(in Rs):			
	- Basic		43.42	29.57

SIGNIFICANT ACCOUNTING POLICIES

NOTES TO ACCOUNTS

ACCOMPANYING NOTES ARE INTEGRAL PART OF FINANCIAL STATEMENTS.

As Per Our Report of Even Date Attached

Ambani & Associates LLP

Chartered Accountants

FRN - 016923N

For and on behalf of the Board

Hitesh Ambani  
Designated Partner  
(MN-506267)



*Kanwal Kumar Sharma* *Pankaj Marwaha*

Kanwal Kumar Sharma  
(Managing Director)  
DIN - 00526387  
B-34, Surya Enclave, New  
Multan Nagar, Delhi-56

Pankaj Marwaha  
(Director - Marketing)  
DIN - 00526342  
1313, Sector-19 B,  
Chandigarh-160019

Place: New Delhi  
Date: 21st Sep. 2022  
UDIN: 22506267BDPJVH4906



CASH FLOW STATEMENT AS AT 31st MARCH, 2022

( in laks unless otherwise stated)

Particulars	Amounts in (Rs.)	Amounts in (Rs.)
	2021-22	2020-21
<b>A. CASH FLOW FROM OPERATING ACTIVITIES</b>		
Net Income/(Loss) before tax and extraordinary items	633.73	369.26
Adjusted for:		
Depreciation	-	-
Other Income - Interest Income	354.15	363.68
Provision for Income Tax	(0.51)	(14.93)
	(233.59)	(100.00)
<b>Operating Profit/(Loss) before working capital changes Adjusted for:</b>	<b>753.78</b>	<b>618.02</b>
Increase/ (Decrease) Accounts Receivable	(1,360.36)	(232.44)
(Increase)/ Decrease Inventories	(1,356.35)	(543.35)
Increase/ (Decrease) in Loans & Advances	(0.41)	(58.44)
(Increase)/ Decrease Short-Term Borrowings	1,035.48	137.67
(Increase)/ Decrease Trade Payables	250.17	404.07
(Increase)/ Decrease in Current Liabilities	(1.44)	330.04
(Increase)/ Decrease in Provisions	157.69	(66.76)
<b>CASH GENERATED FROM OPERATIONS</b>	<b>(1,275.21)</b>	<b>(29.21)</b>
<b>NET CASH OUTFLOW FROM OPERATING ACTIVITIES</b>	<b>(521.43)</b>	<b>588.81</b>
<b>B. CASH FLOWS FROM INVESTING ACTIVITIES</b>		
Purchase of Fixed Assets	(773.65)	(570.15)
Sale of Fixed Assets	31.68	-
Proceeds from Other Non-Current Assets	150.22	(23.74)
Other Income - Interest Income	0.51	14.93
<b>NET CASH FLOWS FROM INVESTING ACTIVITIES</b>	<b>(591.24)</b>	<b>(578.96)</b>
<b>C. CASH FLOWS FROM FINANCING ACTIVITIES</b>		
Decrease in Long Term in Borrowings	1,177.69	(41.97)
Redemption of Preference shares	(30.00)	(67.00)
Dividend declared	-	(18.64)
<b>NET CASH FROM FINANCING ACTIVITIES</b>	<b>1,147.69</b>	<b>(127.61)</b>
Net (Decrease) Increase in Cash & Cash Equivalents (A+B+C)	<b>35.01</b>	<b>(117.77)</b>
Cash and cash Equivalents at the beginning of the year	39.42	157.19
<b>Cash and Cash Equivalents at the end of the year</b>	<b>74.43</b>	<b>39.42</b>

SIGNIFICANT ACCOUNTING POLICIES

1

ACCOMPANYING NOTES ARE INTEGRAL PART OF FINANCIAL ST

2

As Per Our Report of Even Date Attached

Ambani & Associates LLP

Chartered Accountants

FRN - 016923N

Hitesh Ambani

Designated Partner

(MN-506267)



For and on behalf of the Board

*Kanwal Kumar Sharma*

Kanwal Kumar Sharma

(Managing Director)

DIN - 00526387

B-34, Surya Enclave, New  
Multan Nagar, Delhi-56

*Pankaj Marwaha*

Pankaj Marwaha

(Director - Marketing)

DIN - 00526342

1313, Sector-19 B,  
Chandigarh-160019

Place: New Delhi

Date: 21st Sep. 2022

UDIN: 22506267BDPJVH4906





# AIMIL PHARMACEUTICALS (INDIA) LIMITED

## SCHEDULE - 3 : SHARE CAPITAL

	As at March 2022		As at March 2021	
	Number	Amount	Number	Amount
(a) Authorised 500000 preference shares of Rs. 100/- each 950000 Equity Shares of Rs.100/- each	5,00,000 9,50,000	500.00 950.00	5,00,000 9,50,000	500.00 950.00
(b) Issued 4,03,000 preference shares of Rs. 100/- each 8,17,560 Equity Shares of Rs.100/- each	4,03,000 8,17,560	403.00 817.56	4,33,000 8,17,560	433.00 817.56
Subscribed & Paid up 4,03,000 preference shares of Rs. 100/- each 8,17,560 Equity Shares of Rs.100/- each	4,03,000 8,17,560	403.00 817.56	4,33,000 8,17,560	433.00 817.56
Total	12,20,560	1,220.56	12,50,560	1,250.56

## b) Reconciliation of shares outstanding at the beginning and at end of the year

Particulars	As at March 2022		As at March 2021	
	Equity Shares Number	Preference Shares Number	Equity Shares Number	Preference Shares Number
Shares outstanding at the beginning of the year	817560.00	4,33,000.00	817560.00	5,00,000.00
Shares issued during the year	-	-	-	-
Shares redemption during the year	-	-	-	-
Shares outstanding at the end of the year	8,17,560.00	4,03,000.00	8,17,560.00	4,33,000.00

## c) Rights, preferences and restrictions attached to shares

Particulars	Number
Equity shares:-	
-with voting rights	817560.00
-with differential voting rights	
i) as to dividend	NIL
ii) as to voting	NIL
iii) otherwise	NIL
Preference shares:-	
-preference rights as to	
i) fixed amount of dividend	NIL
ii) fixed rate of dividend	NIL
iii) repayment of capital on winding up	NIL
- Categorization	
i) cumulative preference shares	NIL
ii) Non-cumulative preference shares	403000.00
iii) Redeemable preference shares	NIL
iv) Convertible preference shares	NIL
v) Non-convertible preference shares	NIL
vi) other preference shares	NIL

d) Company is not a subsidiary of any company, so, details of Shares held by the holding company, the



ultimate holding company, their subsidiaries and associates is not applicable.

e) (i) The details of shareholding holding more than 5% of aggregate shares in company (Equity Shares)			
Name of Shareholder	As at March 2022		As at March 2021
	No. of Shares held	% of Holding	No. of Shares held
Kanwal Kumar Sharma	1,95,915	23.96	1,95,915
Manjula Sharma	1,66,185	20.33	1,66,185
Amil Marketing Services Pvt. Ltd.	2,94,860	36.07	2,94,860
			23.96
			20.33
			36.07

e) (ii) The details of shareholding holding more than 5% of aggregate shares in company (Preference Shares)			
Name of Shareholder	As at March 2022		As at March 2021
	No. of Shares held	% of Holding	No. of Shares held
Anil Panthi	2,30,000	57.07	2,30,000
R.P. Chhabra	75,000	18.61	75,000
Shyam Sunder Chhabra	25,000	6.20	25,000
Vimal Chhabra	25,000	6.20	25,000
			53.12
			17.32
			5.77
			5.77

f) (i) The details of shares in company held by promoter (Equity Shares)			
Name of promoter	As at March 2022		As at March 2021
	No. of Shares held	% of Holding	No. of Shares held
Kanwal Kumar Sharma	1,95,915	23.96	1,95,915
Manjula Sharma	1,69,185	20.69	1,69,185
Pankaj Marwaha	22,850	2.79	22,850
Suresh Kumar Jinal	20,150	2.46	20,150
Priya Marwaha	2,250	0.28	2,250
Savita Arora	5,000	0.61	5,000
Nitika Kohli	8,900	1.09	8,900
Ikshat Sharma	47,035	5.75	47,035
Kanwal Kumar Sharma (H.U.F)	3,550	0.43	3,550
Amil Marketing Services Pvt. Ltd.	2,94,860	36.07	2,94,860
Sanchit Sharma	38,475	4.71	38,475
Pooja Sharma	4,400	0.54	4,400
Sugandha Marwaha	990	0.12	990
Prince Joshi	4,000	0.49	4,000
			0.12
			0.49

f) (ii) The details of shares in company held by promoter (Preference Shares)			
Name of promoter	As at March 2022		As at March 2021
	No. of Shares held	% of Holding	No. of Shares held
Rajesh Pandey	19,000	4.71	19,000
P. Vasant	5,500	1.36	5,500
Suresh Jain	15,000	3.72	15,000
Anil Panthi	2,00,000	49.63	2,00,000
Shyam Sunder Chhabra	25,000	6.20	25,000
Vimal Chhabra	25,000	6.20	25,000
R.P. Chhabra	75,000	18.61	75,000
Seema Chhabra	6,500	1.61	6,500
Asha Gupta	17,500	4.34	17,500
Anil Arora	5,000	1.24	5,000
S.P. Srivastava	1,000	0.25	1,000
Rashmi Srivastava	1,000	0.25	1,000
Hasan Nawab	1,000	0.25	1,000
Sanjay Bhatnagar	6,500	1.61	6,500
			1.50
			1.50







# AIMIL PHARMACEUTICALS (INDIA) LIMITED

Particulars	AS AT 31.03.2022	AS AT 31.03.2021
<b>SCHEDULE - 4 : RESERVES AND SURPLUS</b>		
<b>Securities Premium Account</b>		
Opening Balance		
Add : Securities premium credited on Share issue	64.80	64.80
Less : Premium Utilised for various reasons	-	-
Premium on Redemption of Debentures	-	-
For Issuing Bonus Shares	-	-
Closing Balance	64.80	64.80
<b>Capital Redemption Reserve</b>		
Opening Balance		
(+) Current Year Transfer	67.00	-
(-) Written Back in Current Year	30.00	67.00
Closing Balance	97.00	67.00
<b>Other Reserves (Specify the nature and purpose of each reserve)</b>		
<b>General Reserve</b>		
Opening Balance		
(+) Current Year Transfer	5.17	5.17
(-) Written Back in Current Year	-	-
Closing Balance	5.17	5.17
<b>h. Surplus</b>		
Opening balance		
(+) Net Profit/(Net Loss) For the current year	1,923.16	1,767.02
(-) Proposed Dividends	355.02	241.78
(-) Transfer to Capital Redemption Reserves	-	18.64
Closing Balance	30.00	67.00
<b>Total</b>	<b>2,248.18</b>	<b>1,923.16</b>
<b>SCHEDULE - 5 : LONG TERM BORROWINGS</b>		
<b>Secured</b>		
(a) Bonds/debentures		
(b) Term loans		
- From Banks (Term Loan)		
(Secured against Plant & Machinery of company and personal guarantee of Directors	267.45	366.77
- From Banks (Vehicles Loan)		
(Secured against hypothentication of Vehicles)	81.02	97.25
<b>Total</b>	<b>348.47</b>	<b>464.02</b>
<b>SCHEDULE - 6 OTHER LONG TERM LIABILITIES</b>		
<b>Unsecured</b>		
Security Deposits		
<b>Total</b>	<b>5,413.43</b>	<b>4,120.20</b>
<b>SCHEDULE - 7 : DEFERRED TAX LIABILITIES</b>		
Deferred Tax Liabilities on Fixed Assets		
	93.05	47.93
	<b>93.05</b>	<b>47.93</b>





# AIMIL PHARMACEUTICALS (INDIA) LIMITED

## Particulars

### SCHEDULE - 8 : SHORT - TERM BORROWINGS

#### Secured

#### (a) Loans repayable on demand

From banks Cash credits Loan

(Secured against Hypothecation of stocks, Debtors, including Govt. Bills, equitable mortgage on immovable properties, plant & machinery of existing unit and personal guarantee of Directors, rate of interest charged is 12%)

From banks (Guaranteed Emergency Credit Line (GECL-Covid -19))

(Secured by Govt., Rate of interest charged is 8%.)

Current maturities of long-term debt

Secured Loans

- From Banks (Term Loan)

- From Banks (Vehicles Loan)

#### Total

### SCHEDULE - 10 : OTHER CURRENT LIABILITIES

Expenses Payable\*

(\* It includes Electricity Exp, Telephone exp., Audit fee and other related exp.)

### SCHEDULE - 11 : SHORT - TERM PROVISIONS

#### (a) Provision for employee benefits

Salary & Reimbursements

Contribution to ESI/PF

#### (b) Income Tax Provision

### SCHEDULE - 13 : OTHER NON-CURRENT ASSETS

Security Deposits

Secured, considered good

Unsecured, considered good

Bank deposits with more than 12 months maturity

### SCHEDULE - 14 : INVENTORIES

(As verified and certified by the management )

a. Raw Materials and components ( Valued at cost or net reliable value, whichever is less)

Goods-in transit

b. Work-in-progress ( Valued at cost or net reliable value, whichever is less)

Goods-in transit

c. Finished goods (Valued at cost or net reliable value, whichever is less)

Goods-in transit

g. Others (Specify nature)

Packing Material (Valued at cost or net reliable value, whichever is less)

Goods-in transit

### SCHEDULE - 16 : CASH AND BANK BALANCE

i) Cash & Cash Equivalents:

a. Balances with banks

b. Cheques, drafts on hand

c. Cash on hand

d. Others (Please specify)

Bank deposits with less than 12 months maturity

AS AT  
31.03.2022

AS AT  
31.03.2021

4,041.55

4,101.94

1,375.70

279.82

97.15

120.00

46.60

33.85

5,561.00

4,535.61

1,030.51

1,021.85

1,030.51

1,021.85

960.67

967.33

106.90

104.96

289.40

127.01

1,356.98

1,199.29

1,475.29

1,630.50

31.14

26.15

1,506.43

1,656.65

1,427.48

749.72

337.21

284.40

1,820.26

1,163.48

117.90

139.00

816.09

825.99

4,518.94

3,162.59

58.27

20.53

16.16

13.89

74.43

39.42







**AIMIL PHARMACEUTICALS (INDIA) LIMITED**  
2994/4, STREET NO-17, RANJEET NAGAR, NEW DELHI - 110008  
CIN - U24231DL1984PLC019461

**Notes Annexed to & forming part of Balance Sheet for the year ended 31st March, 2022**

( in Lakhs unless otherwise stated)

**Note : 9 Trade Payables**

Particulars	Year Ended 31.3.2022					Year Ended 31.3.2021				
	Outstanding for following periods from due date of payment					Outstanding for following periods from due date of payment				
	Less than 1 year	1-2 years	2-3 years	More than 3 years	Total	Less than 1 year	1-2 years	2-3 years	More than 3 years	Total
i MSME	32.57	15.65	7.57	1.84	57.63	30.83	14.81	7.16	1.74	54.55
ii Others	3,494.13	5.21	5.42	2.42	3,507.18	3,246.61	6.85	4.51	2.13	3,260.09
iii Disputed dues - MSME					-					-
iv Disputed dues - Others					-					-
<b>Total</b>	<b>3,526.70</b>	<b>20.86</b>	<b>12.99</b>	<b>4.26</b>	<b>3,564.81</b>	<b>3,277.43</b>	<b>21.66</b>	<b>11.68</b>	<b>3.87</b>	<b>3,314.64</b>

\*Details of trade payables are based on the information available with the company regarding the status of suppliers as defined under the Micro, Small & Medium Enterprises Development Act' 2006. The amount due to MSME for the period ended 31.03.2022 is Nil ( Previous Year Nil). No interest in terms of Section 16 of MSME Act 2006 or otherwise has either been paid or payable or accrued & remaining unpaid as at 31st March 2022. There are no amounts payable to SSI units.

**Note : 15 Trade Receivables**

Note : 15 Trade Receivables													
Particulars		Year Ended 31.3.2022					Year Ended 31.3.2021						
		Outstanding for following periods from due date of payment					Outstanding for following periods from due date of payment						
		Less than 6month	6month – 1 year	1-2years	2-3years	More than 3 years	Total	Less than 6month	6month – 1 year	1-2years	2-3years	More than 3 years	Total
i	Undisputed Trade receivables – considered good	11,299.07	222.19	76.55	52.49	6.99	11,657.28	9,950.21	228.56	65.61	46.36	6.18	10,296.92
ii	Undisputed Trade Receivables – considered doubtful												
iii	Disputed Trade Receivables considered good						-						-
iv	Disputed Trade Receivables considered doubtful						-						-
	Total	11,299.07	222.19	76.55	52.49	6.99	11,657.28	9,950.21	228.56	65.61	46.36	6.18	10,296.92





# AIMIL PHARMACEUTICALS (INDIA) LIMITED

2994/4, STREET NO-17, RAJEEET NAGAR, NEW DELHI - 110008

SCHEDULE 12 : SCHEDULE OF FIXED ASSETS AND DEPRECIATION THEREON FOR THE PERIOD FROM 01 April,2021 to 31 Mar. 2022

GROSS BLOCK				DEPRECIATION				NET BLOCK	
As At 01.04.2021	Additions	Sale Adjustment	As At 31.03.2022	Upto 31.03.2021	Additional	For the Year Current	Sale Adjustment	Upto 31.03.2022	As At 31.03.2022
A. Land	84.07	-	84.07	-	-	-	-	-	84.07
B. Building	2,278.23	247.49	2,525.72	1,084.31	-	117.20	0.02	1,201.49	1,324.23
C. Plant & Machinery	2,671.91	190.42	2,862.32	1,838.54	-	140.56	-	1,979.10	883.22
D. Computers	204.03	12.17	216.21	178.89	-	13.90	0.00	192.79	23.42
E. Vehicles	624.61	47.37	579.63	522.38	-	32.91	85.65	469.64	109.99
F. Furniture & Fixtures	263.90	3.33	267.23	172.18	-	23.58	-	195.76	71.47
G. Office Equipment	171.82	15.32	187.13	146.61	-	11.50	-	158.11	29.02
H. Electric equipment	7.40	-	7.40	7.14	-	-	-	7.14	0.26
I. Cable Wires	83.34	38.47	121.82	45.97	-	13.36	-	59.33	62.48
J. Software	2.90	4.08	6.98	1.42	-	1.13	-	2.55	4.43
TOTAL (A)	6,392.21	558.64	6,858.50	3,997.44	-	354.15	85.68	4,265.91	2,592.59
Capital Work in Progress	119.40	214.49	308.89	-	-	-	-	-	308.89
TOTAL (B)	119.40	214.49	308.89	-	-	-	-	-	308.89
TOTAL (A+B)	6,511.61	773.14	7,167.39	3,997.44	-	354.15	85.68	4,265.91	2,901.48
Previous Year	5,946.28	570.41	6,511.61	3,638.58	-	363.68	-	3,997.44	2,514.17







# AIMIL PHARMACEUTICALS (INDIA) LIMITED

	AS AT 31.03.2022	AS AT 31.03.2021
<b>SCHEDULE - 17 : SHORT - TERM LOANS AND ADVANCES</b>		
Others Short-Term Loans and Advances*		
*(The Short-Term Loans and Advances are Unsecured, considered good)	343.19	342.78
	<b>343.19</b>	<b>342.78</b>
<b>SCHEDULE - 18 : REVENUE FROM OPERATIONS</b>		
Domestic Sales		
Export sales	43,137.56	39,464.51
	1,568.11	767.30
	<b>44,705.68</b>	<b>40,231.81</b>
<b>SCHEDULE - 19 : OTHER INCOME</b>		
Interest Income	0.51	5.25
Miscellaneous Income	53.03	42.93
	<b>53.54</b>	<b>48.18</b>
<b>SCHEDULE - 20 : COST OF MATERIALS CONSUMED</b>		
<u>Raw Material Consumed</u>		
Opening Stock		
Add : Purchases during the year	1,034.12	1,009.56
Less : Closing Stock	6,708.95	4,981.90
Less : Expenses incurred on R & D	1,764.69	1,034.12
Raw Material Consumed	179.35	148.72
	<b>5,799.03</b>	<b>4,808.61</b>
<u>Packing Material Consumed</u>		
Opening Stock		
Add : Purchases during the year	825.99	535.60
Less : Closing Stock	3,500.55	3,117.96
Packing Material Consumed	816.09	825.99
	<b>3,510.45</b>	<b>2,827.57</b>
Total Rs...	<b>9,309.48</b>	<b>7,636.18</b>
<b>SCHEDULE - 21 : Changes in Inventories of Finished Goods and WIP</b>		
<u>Opening Stock</u>		
Finished Stock		
Goods in Transit	1,163.48	1,000.67
	139.00	73.42
	<b>1,302.48</b>	<b>1,074.09</b>
<u>Closing Stock</u>		
Finished Stock	1,820.26	1,163.48
Goods in Transit	117.90	139.00
	<b>1,938.16</b>	<b>1,302.48</b>
Total Rs...	<b>(635.68)</b>	<b>(228.39)</b>




**AIMIL PHARMACEUTICALS (INDIA) LIMITED**

	AS AT 31.03.2022	AS AT 31.03.2021
<b>SCHEDULE - 22 : EMPLOYEE BENEFITS EXPENSE</b>		
(a) Salaries and incentives	10,867.61	9,194.90
(b) Contributions to -		
(i) Provident fund		
(ii) Superannuation scheme		
(iii) ESI	435.33	340.32
(c) Gratuity fund contributions	65.95	64.92
(d) Social security and other benefit plans		
(e) expense on Employee Stock Option Scheme (ESOP) and Employee Stock Purchase Plan (ESPP),		
(f) Staff welfare expenses	212.67	158.72
	<b>11,581.55</b>	<b>9,758.86</b>
<b>SCHEDULE - 23 : FINANCE COST</b>		
Interest Expenses	1,175.22	1,103.54
Other Borrowing Costs		
Applicable net gain/loss on foreign currency transactions and translation		
	<b>1,175.22</b>	<b>1,103.54</b>
<b>SCHEDULE - 24 : OTHER EXPENSES</b>		
Rent, Rates & Taxes	432.19	374.85
Fine & Penalty	46.00	15.42
Postage, Telegram & Telephones	63.77	33.31
Printing & Stationery	38.94	22.15
Conference Expenses	136.56	55.21
Electricity & water Expenses	42.62	45.45
Conveyance	55.29	84.03
Flood loss		453.71
Charity & Donation	0.66	2.77
Bank Charges	31.90	27.46
Insurance Charges	21.42	41.87
Fees & Subscription	12.88	13.98
Legal & Professional Expenses	112.70	126.53
General Expenses	24.67	22.53
Diwali Expenses	11.46	0.69
Office Repair & Maintenance	72.89	51.68
Vehicle Running & Maintenance	49.19	37.15
Payment to Auditors - Audit Fees	16.00	16.00
- Other Expenses	5.25	5.25
Security Service Charges	37.15	32.99
Travelling Expenses	150.06	76.22
Books & Periodicals	0.75	0.05
Additional Sales Tax Paid	2.38	0.11
Royalty	66.80	76.99
Advertisement & Publicity	87.82	46.36
Octroi, Freight & Cartage Outward	1,095.46	741.62
Expiry & Breakages	770.25	1,189.73
Sales Promotion & Selling Expenses	15,831.85	14,684.19
C & F Commission & Expenses	360.53	317.79
Freight & Cartage	145.87	115.62
Power & Fuel	637.12	505.45
Repair & Maintenance - Machinery	62.76	58.42
- Buildings	33.72	23.74
- Others	7.68	7.69
Other Manufacturing Expenses	162.54	41.51
Expenses incurred on R & D	289.55	279.75
	<b>20,916.67</b>	<b>19,628.29</b>





## **Schedule 1: Significant Accounting Policies**

**(Annexure to and forming part of the Balance Sheet as on 31.03.2022 and Profit & Loss Account for the year ended on that date)**

### **1.01 Basis of preparation**

The accounts have been prepared on historical cost convention as a going concern on accrual basis, in accordance with the requirements of the Companies Act, 2013 and in accordance with the accounting principles generally accepted in India, and comply with the accounting standards notified under the Companies (Accounting Standards) Rules, 2006 (as amended), to the extent applicable. Accounting policies have been consistently applied and where a newly issued accounting standard is initially adopted or a revision to an existing accounting standard requires a change in the accounting policy hitherto in use, such changes are suitably incorporated. The management evaluates all recently issued or revised accounting standards on an ongoing basis.

### **1.02 Presentation and disclosure of financial statements**


The presentation and disclosure of the financial statements have been made in accordance with the revised Schedule III to the Companies Act, 2013. Schedule III of Companies Act, 2013 came into force with effect from the 1st April, 2014 vide Notification S.O.902(E), dated 26th March 2014 and subsequently amended vide Notification G.S.R. 679(E), dated 4th September 2015, vide Notification G.S.R. 404(E), dated 6th April 2016 and vide Notification G.S.R. 1022(E), dated 11th October, 2018 and very recently vide Notification G.S.R. 207(E), dated 24th March, 2021. The adoption of revised schedule III does not impact recognition and measurement principles followed for preparation of financial statements. However, it has significant impact on presentation and disclosures made in the financial statements. The Company has also reclassified the previous year figures in accordance with the requirements applicable in the current year.

### **1.03 Use of Estimates**

The preparation of financial statements in conformity with generally accepted accounting principles in India requires the management to make judgments, estimates and assumptions that affect the reported amounts of revenues, expenses, assets and liabilities and the disclosure of contingent liabilities, at the end of the reporting period. Although these estimates are based on the management's best knowledge of current events and actions, uncertainty about these assumptions and estimates could result in the outcomes requiring a material adjustment to the carrying amounts of assets or liabilities in future periods.

### **1.04 Fixed Assets**

- a) Tangible assets are stated at their original cost of acquisition including taxes, duties, freight, and other incidental expenses related to acquisition and installation of the concerned assets less accumulated depreciation and impairment losses, if any. Interest and other borrowing costs during construction period to finance qualifying fixed assets are capitalized.
- b) Subsequent expenditure related to an item of tangible asset is added to its book value only if it increases the future benefits from the existing asset beyond its previously assessed standard of performance. All other expenses on existing tangible assets,



including day to day repair and maintenance expenditure are charged to the statement of profit and loss for the period during which such expenses are incurred.

- c) Preoperative expenditure and trial run expenditure accumulated as capital work in progress is allocated on the basis of prime cost of fixed assets in the year of commencement of commercial production.
- d) Intangible assets are recognized if it is probable that the future economic benefits that are attributable to the asset will flow to the Company and cost of the assets can be measured reliably.

#### **1.05 Depreciation**

- a) Depreciation has been provided on Written down value method at the rates and in the manner as prescribed in Schedule II of the Companies Act, 2013 which approximate the useful life of the assets estimated by the management. The residual values and useful life of assets are reviewed and adjusted, if appropriate, at each balance sheet date. Depreciation on fixed assets added/disposed off during the year is provided on pro-rata basis. Depreciation on assets for a value not exceeding Rs.5000 acquired during the year is provided at the rate of 100%.
- b) The cost and the accumulated depreciation on fixed assets sold or otherwise disposed off are removed from the stated values and resulting gain and losses are recognized in profit and loss account.

#### **1.06 Inventories**

- a) Raw materials, components, stores and spares are valued at lower of cost and net realizable value. However, materials and other items held for use in the production of inventories are not written down below cost if the finished products in which they will be incorporated are expected to be sold at or above cost. Cost of raw materials, components and stores and spares is determined on a moving weighted average basis.
- b) Work-in-progress and finished goods are valued at lower of cost and net realizable value. Cost includes direct materials and labour and a proportion of manufacturing overheads based on normal operating capacity. Cost of finished goods includes excise duty and is determined on a weighted average basis.
- c) The stocks of scrap materials have been taken at net realisable value.

#### **1.07 Retirement Benefits**

Contributions to defined contribution scheme such as provident fund etc. are charged to profit & loss account as incurred. The company also provides for retirement /Post Retirement benefits in form of gratuity, pensions and medical. Such benefits are recognized as an expense as and when incurred.

#### **1.08 Revenue Recognition**

Revenue is recognized to the extent that it is probable that the economic benefits will flow to the group and the revenue can be reliably measured. Revenue from sales are recognized when significant risks and rewards of ownership of the goods have passed to the buyer which coincides with delivery and are recorded net of returns. Sales are exclusive of sales tax, value added tax & Goods and Service Tax. Sales do not include inter-divisional/Branch transfers.





### 1.09 Earnings per Share

Basic earnings per share are calculated by dividing the net profit or loss for the period attributable to equity shareholders by the weighted average number of equity shares outstanding during the period. For the purpose of calculating diluted earnings per share, the net profit or loss for the period attributable to equity shareholders and the weighted average number of shares outstanding during the period are adjusted for the effects of all dilutive potential equity shares. The number of shares and dilutive shares are adjusted by issue of bonus shares, if any.

### 1.10 Taxes on Income

Tax expense for the year comprises of current tax and deferred tax.

- a) Current tax is determined on the amount of tax payable in respect of taxable income for the period, using the applicable tax rates and tax laws in accordance with the provisions of Income Tax Act 1961.
- b) Deferred tax is recognized, subject to consideration of prudence, on timing differences, being difference between taxable and accounting income that originate in one period and are capable of reversal in one or more subsequent periods. Deferred tax is accounted for using the tax rates and laws that have been enacted or substantively enacted as on the Balance Sheet date. Deferred tax assets are recognized only to the extent that there is reasonable certainty that sufficient future taxable income will be available against which such deferred tax assets can be realized. At each reporting date, the group re-assesses unrecognized deferred tax assets. It recognizes unrecognized deferred tax asset to the extent that it has become reasonably certain or virtually certain, as the case may be, that sufficient future taxable income will be available against which such deferred tax assets can be realized.

### 1.11 Impairment of assets

The group assesses at each reporting date whether there is an indication that an asset may be impaired. If any indication exists, or when annual impairment testing for an asset is required, the company estimates the asset's recoverable amount. An asset's recoverable amount is the higher of an assets or cash-generating unit's (CGU) net selling price and its value in use. The recoverable amount is determined for an individual asset, unless the asset does not generate cash inflows that are largely independent of those from other assets or groups of assets. Where the carrying amount of an asset or CGU exceeds its recoverable amount, the asset is considered impaired and is written down to its recoverable amount. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset. In determining net selling price, recent market transactions are taken into account, if available. If no such transactions can be identified, an appropriate valuation model is used. Impairment losses of continuing operations, including impairment on inventories, are recognized in the statement of profit and loss. After impairment, depreciation is provided on the revised carrying amount of the asset over its remaining useful life.

### 1.12 Borrowing costs



Borrowing cost includes interest and other costs incurred in connection with the arrangement of borrowings and exchange differences arising from foreign currency borrowings to the extent they are regarded as an adjustment to the interest cost. Borrowing costs directly attributable to the acquisition, construction or production of an asset that necessarily takes a substantial period of time to get ready for its intended use or sale are capitalized as part of the cost of the respective asset. All other borrowing costs are expensed in the period they occur.

#### **1.13 Foreign Currency Transaction**

Foreign Currency Transaction are recorded in the reporting currency by applying to the foreign currency amount, the exchange rate between the reporting currency and the foreign currency at the date of transaction. Foreign currency monetary items are retranslated using the exchange rate prevailing on the reporting date. Exchange differences arising on the settlement of the monetary items or on reporting such monetary items of the company at the rate different from those at which they were initially recorded during the year or reported in previous year financial statements are recognized as income or expense in the year in which they arise.

#### **1.14 Provisions and Contingent Liabilities**

##### **Provisions**

A provision is recognized when the group has a present obligation as a result of past event, it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation and a reliable estimate can be made of the amount of the obligation. Provisions are not discounted to their present value and are determined based on the best estimate required to settle the obligation at the reporting date. These estimates are reviewed at each reporting date and adjusted to reflect the current best estimates.

##### **Contingent Liabilities**

A contingent liability is a possible obligation that arises from past events whose existence will be confirmed by the occurrence or non-occurrence of one or more uncertain future events beyond the control of the group or a present obligation that is not recognized because it is not probable that an outflow of resources will be required to settle the obligation. A contingent liability also arises in extremely rare cases where there is a liability that cannot be recognized because it cannot be measured reliably. The company does not recognize a contingent liability.

- 1.15** Accounting policies not specifically referred to otherwise are in consonance with generally accepted accounting policies.





**Schedule 2: Notes to Accounts**

(Annexure to and forming part of the balance sheet as on 31.03.2022 and Profit & Loss Account for the year ended on that date)

**2.1 Cash and cash equivalents**

(Figures are in lakhs)

Cash and cash equivalents comprise cash at bank and in hand and short-term investments with an original maturity of three months or less.

**2.2 Deferred Tax Liability**

	Amount Rs.
W.D.V As per Companies Act, 2013	2901.47
W.D.V As Per Income Tax Act, 1961	2543.60
Difference	357.87
Deferred Tax Liabilities as on 31.03.2022	93.05
Deferred Tax Liabilities as on 31.03.2021	47.93
Provision to be made for FY 2021-22	45.12

**2.3 Auditor's Remuneration consists of followings:**

	<u>2021-22</u>	<u>2020-21</u>
Audit Fees	15.00	15.00
Tax Audit Fees	1.00	1.00
Other Matters	3.50	3.50
Other Expenses	<u>1.75</u>	<u>1.75</u>
<b>TOTAL</b>	<b>21.25</b>	<b>21.25</b>

**2.4 Particulars of Remuneration Paid to Directors**

	<u>2021-22</u>	<u>2020-21</u>
Managing Director	36.00	36.00
Other Directors	<u>107.97</u>	<u>107.97</u>
<b>TOTAL</b>	<b>143.97</b>	<b>143.97</b>

**2.5** The Earning Per Share (EPS) comes to Rs. 43.42 per share (Previous year Rs. 29.57 per share on 8,17,560 Equity Shares) on 8,17,560 Equity Shares on annual basis.

**2.6** The outstanding balances as at 31st March, 2022 in respect of Sundry Creditors, Trade Receivables and Bank Balances are subject to confirmation and reconciliation.

**2.7** In the opinion of the board all Current Assets, Loans & Advances are approximately of the value stated if realized in the ordinary course of the business.




## 2.8 Additional Regulatory Information

### i) Ratio Analysis:

S.No.	Ratio Type	Numerator	Denominator	Ratio as at 31.03.2022	Numerator	Denominator
1	Current Ratio	Total current assets	Total current liabilities	1.44	16,593.84	11,513.29
2	Debt-Equity Ratio	Total Debts	Total Shareholders Fund	0.10	348.47	3,635.71
3	Debt Service Coverage Ratio	-	-	-	-	-
4	Return on Equity Ratio	Net Profit after tax for the year	Shareholder's fund	0.10	355.02	3,635.71
5	Inventory Turnover Ratio	Revenue from operations	Average inventory	11.64	44,705.68	3,840.77
6	Trade Receivables Turnover Ratio	Revenue from operations	Average Accounts Receivable	4.07	44,705.68	10,977.10
7	Trade Payables Turnover Ratio	Purchases	Average trade payables	0.41	1,424.10	3,439.72
8	Net Capital Turnover Ratio	Revenue from operations	Shareholder's fund	12.30	44,705.68	3,635.71
9	Net Profit Ratio	Profit for the year	Revenue from operations	0.01	633.73	44,705.68
10	Return on Capital Employed	Profit before tax and finance cost	Capital Employed	0.45	1,808.95	3,984.18
11	Return on Investment	-	-	-	-	-

- ii) The Company does not have any immovable property for which title deeds are not held in the name of the company.
- iii) The Company has not done any revaluation of Property, Plant & Equipment during the year.
- iv) The Company has not provided any loans or advances to promoters, directors, KMPs and the related parties during the year.
- v) The Company does not hold any Benami property under the Benami Transactions (Prohibition) Act, 1988 and rules made thereunder.
- vi) The Company has not availed borrowings from banks or financial institutions on the basis of Security of current assets.
- vii) The Company has not been declared a wilful defaulter by any bank or financial institutions or other lender during the financial year.
- viii) The Company does not have transactions with companies struck off under section 248 of the Companies Act 2013 or section 560 of Companies Act 1956.
- ix) The Company does not have any charges or satisfaction which is yet to be registered with the Registrar of Companies (ROC) beyond the statutory period.





- x) The Company has not advanced or loaned or invested funds to any other person(s) or entity(ies), including foreign entities(intermediaries), with the understanding that the intermediary shall;
- Directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Company (Ultimate Beneficiaries), or
  - Provide any guarantee, security or the like to or on behalf of the Ultimate Beneficiaries.
- xi) The Company has not received any funds from any person(s) or entity(ies), including foreign entities (Funding Party) with the understanding (whether recorded in writing or otherwise) that the Company shall;
- Directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party (Ultimate beneficiaries), or
  - Provide any guarantee, security or the like to or on behalf of the Ultimate Beneficiaries.
- xii) The Company does not have any transactions which are not shown in the books of accounts that has been surrendered as income during any tax assessment.
- xiii) The Company has not traded or invested in crypto currency or virtual currency during the financial year.
- xiv) The Company has complied with the number of layers prescribed under clause (87) of section 2 of the Companies Act 2013 read with Companies (Restrictions on number of layers) Rules, 2017.
- xv) The Company has not entered into any scheme of arrangements prescribed under section 230 to 237 of Companies Act, 2013.
- 2.9 In accordance with provisions of Accounting Standard - 28 issued by the ICAI on impairment of assets, the company has carried out an impairment test in respect of major assets. On the basis of such exercise, the company has determined that for the year ended 31st March 2022, no provision of impairment loss is required.

2.10 **Foreign Currency Transactions**

Particulars	31-Mar-22	31-Mar-21
(i) Earning in Foreign Currency	393.08610	269.94021
(ii) Expenditure in foreign Currency		
(a) CIF Value of import		
Machinery & Equipment	-	-
Stores & Spares	-	-
Other Consumables	-	-
(b) Expenses (Purchases)	15.04471	11.84028



"जय माता दी"

- 2.11 Segment Reporting - The company operates in two geographical segment in terms of AS-17.

(Rs. in Crores)


Particulars	SEGMENT-NARAINA	SEGMENT-NALAGARH	TOTAL
REVENUE	113.97	333.09	447.06
PROFIT	1.62	4.72	6.34
ASSETS	6.69	22.33	29.02

- 2.11 Retirement Benefits: Provision for Provident Fund and ESI has been made by the company.


- 2.12 Previous year figures were regrouped or rearranged wherever necessary.

**Ambani & Associates LLP**  
Chartered Accountants  
FRN-016923N

For and behalf of the Board

  
(Hitesh Ambani)  
M.N.- 506267  
Designated Partner



  
**Kanwal Kumar Sharma**  
(Managing Director)

  
**Pankaj Marwaha**  
(Director - Marketing)

Place: New Delhi  
Date: 21.09.2022

UDIN: 22506267BDPJVVH4906



# Annexure 'A' to Notes to Accounts

Accounting Standard (AS-18) – “Related Party Disclosure” (Current Year)		
S.N.	Description Of Related Party	Name of Related Party
1	Key Management Personnel	a. Mr. K. K. Sharma - Managing Director b. Mr. Pankaj Marwaha - Director Marketing c. Mrs. Manjula Sharma - Director d. Mr. Satya Prakash Srivastava - Director e. Mr. Ikshit Sharma - Director
2	Relatives of Key Management Personnel	a. Mr. Sanchit Sharma - Son of Managing Director b. Mrs. Pooja Sharma - Wife of Mr. Ikshit Sharma c. Mrs. Sugandha Marwaha - Wife of Mr. Sanchit Sharma d. Mrs. Priya Marwaha - Wife of Mr. Pankaj Marwaha e. Mrs. Nitika Kohli - Daughter of MD Sir f. Mrs. Rashmi Srivastava - Wife of Director g. Mrs. Pragya Chadha - Daughter in Law of Director h. Mr. Kartik Marwaha - Son of Director

Accounting Standard (AS-18) – “Related Party Disclosure” (Last Year)		
S.No	Description Of Related Party	Name of Related Party
1	Key Management Personnel	a. Mr. K. K. Sharma - Managing Director b. Mr. Pankaj Marwaha - Director Marketing c. Mrs. Manjula Sharma - Director d. Mr. Satya Prakash Srivastava - Director e. Mr. Ikshit Sharma - Director
2	Relatives of Key Management Personnel	a. Mr. Sanchit Sharma - Son of Managing Director b. Mrs. Pooja Sharma - Wife of Mr. Ikshit Sharma c. Mrs. Sugandha Marwaha - Wife of Mr. Sanchit Sharma d. Mrs. Priya Marwaha - Wife Of Mr. Pankaj Marwaha e. Mrs. Nitika Kohli - Daughter of MD Sir f. Mrs. Rashmi Srivastava - Wife of Director g. Mrs. Jyotsana Sharma - Daughter of Director h. Mr. Kartik Marwaha - Son of Director i. Mrs Subhash Sharma - Sister of MD Sir



Transactions with related party: -

(Figures are in lakhs)

Particulars	Key Management Personnel		Relatives of KMP	
	31/03/2022	31/03/2021	31/03/2022	31/03/2021
<b>Director's Remuneration</b>				
Mr. K. K. Sharma	36.00	36.00		
Mr. Pankaj Marwaha	24.00	24.00		
Mrs. Manjula Sharma	36.00	36.00		
Dr. Ikshit Sharma	36.00	36.00		
Mr. S. P. Srivastava	11.97	11.97		

<b>Salary</b>				
Mr. Sanchit Sharma			36.00	36.00
Mrs. Pooja Sharma			36.00	36.00
Mrs. Sugandha Marwaha			36.00	36.00
Mrs. Priya Marwaha			9.61	9.61
Mrs. Nitika Kohli			36.00	36.00
Mrs. Rashmi Srivastava			7.86	7.86
Mr. Kartik Marwaha			24.00	24.00
Mrs. Pragya Chadha			15.00	-

Closing Balance of Long-Term Borrowings from Related Parties is NIL.

